| 生物活性 |
IU1 is a selective and reversible USP14 inhibitor with an IC50 of 4-5 μM that binds to the catalytic cleft of USP14 to block deubiquitinase activity, induces calpain-dependent Tau cleavage, causes ATP depletion, reduces E1~Ub thioester levels and 26S proteasome assembly, enhances the chymotrypsin-like activity of the 26S proteasome, regulates LC3B-dependent autophagy flux, decreases the proliferation and migration of cancer cells, and blocks the G0/G1-to-S phase cell cycle transition in follicular thyroid cancer cells; furthermore, IU1 activates the autophagy-lysosomal pathway and the ubiquitin-proteasome pathway, induces apoptosis, inhibits the growth of cervical cancer cells, enhances the degradation of proteasome substrates associated with neurodegenerative diseases, accelerates the degradation of oxidized proteins, and improves oxidative stress resistance, making it useful for research on Alzheimer's disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative diseases. |
体外研究 (In Vitro) |
IU1 (75 μM; 6-22 h) 可减少 Prostaglandin J2 (PGJ2) (MS-W54533) 诱导的泛素化蛋白积累,诱导 Tau、α-血影蛋白和半胱天冬酶-3 前体的钙蛋白酶依赖性切割,且不会改变大鼠胚胎 (E18) 大脑皮层神经元培养物中的基础泛素化蛋白水平。 IU1 (5-50 μM; 4-24 h) 呈浓度依赖性和时间依赖性的神经毒性,其中 5 μM IU1 作用 24 h 后会导致细胞活力显著下降,25 μM IU1 早在作用 4 h 时即可诱导毒性。 IU1 (5-80 μM; 4-24 h) 以浓度依赖方式 (24 h 后≥25 μM 时具有显著性) 和时间依赖方式 (25 μM 作用 24 h 后具有显著性) 降低细胞内 ATP 水平。 IU1 可直接抑制线粒体复合物 I 的活性,其对 NADH:Q1 还原酶活性的 IC50 约为 40 μM;该物质对复合物 II 的影响极小,在高浓度下可增强复合物 IV 的活性,且不会改变透化大鼠脑线粒体膜中 ATP 合酶的功能。 IU1 (5-50 μM; 16 h) 可消除基础状态下的 E1-Ub 硫酯水平,降低 PGJ2 诱导的泛素化蛋白积累,且与 PGJ2 联用时可显著降低总 E1 蛋白水平;在大鼠胚胎 (E18) 大脑皮层神经元培养体系中,浓度≤25 μM 的 IU1 对 E1-Ub 硫酯、E1 蛋白及泛素化蛋白水平的影响极小。 IU1 (5-50 μM; 24 h) 可诱导 26S 蛋白酶体的组装与活性呈浓度依赖性下降,同时伴随 20S 蛋白酶体的活性与水平升高;在大鼠胚胎 (E18) 大脑皮质神经元培养体系中,50 μM IU1 引发的效应最为显著。 IU1 (1-100 μM; 24 h) 可剂量依赖性降低 ML1 滤泡状甲状腺癌细胞的活力,在 30、50 和 100 μM 浓度下观察到显著效应,而对人原代甲状腺细胞活力的影响极小。 IU1 (20 μM; 6 h) 可显著降低 ML1 滤泡状甲状腺癌细胞和原代人甲状腺细胞的基础迁移能力,并完全消除 S1P 对 ML1 细胞的迁移刺激作用。 IU1 (20-50 μM; 24 h) 可增强 ML1 滤泡状甲状腺癌细胞中 26S 蛋白酶体的胰凝乳蛋白酶样活性,其中 20 μM 可诱导更强的显著效应。 IU1 (50 μM; 24 h) 可显著抑制 ML1 滤泡状甲状腺癌细胞中 USP14 的催化活性,而 20 μM IU1 对 USP14 的催化活性无显著影响。 IU1 (20 μM; 24 h) 可增强 ML1 滤泡状甲状腺癌细胞中依赖 LC3B 的自噬流,而当与 100 μM CQ 共同处理 4 h 时,会降低人原代甲状腺细胞中依赖 LC3B 的自噬流。 IU1 (20 μM; 24 h) 单独使用或与 100 μM CQ 联合使用时,均不会改变 ML1 滤泡状甲状腺癌细胞或原代人甲状腺细胞中 SQSTM1/p62 的蛋白表达。 IU1 (20 μM; 6 h) 可显著降低 FTC-133 滤泡状甲状腺癌细胞的基础迁移能力。 IU1 (25 μM; 4 h reoxygenation after 8 h OGD) 可提高经 OGD 处理的原代培养 Bend.3 脑内皮细胞中 ZO-1 蛋白的表达水平,从而抑制 OGD 诱导的 ZO-1 表达下调。 IU1 (0.1-100 μM; 24 h; 100 μM; 12, 24, 48 h) 以剂量和时间依赖的方式抑制人宫颈癌 HeLa 和 SiHa 细胞的增殖。 IU1 (2, 50, 100 μM for HeLa; 20, 50, 100 μM for SiHa; 1 week) 可降低人宫颈癌 HeLa 细胞和 SiHa 细胞培养 1 周后的长期集落形成能力。 IU1 (100 μM; 24, 48 h) 可抑制 HeLa 和 SiHa 人宫颈癌细胞的 2D 迁移能力,表现为 24 和 48 h 时伤口愈合率降低。 IU1 (2, 50, 100 μM for HeLa; 20, 50, 100 μM for SiHa; 12 h) 处理 12 h 后可诱导细胞周期 G0/G1 期阻滞,并降低 S/G2/M 期细胞占比。 IU1 (2-100 μM; 12 h) 处理 12 h 后可在人宫颈癌细胞 HeLa 中诱导剂量依赖性凋亡。 IU1 (100 μM; 12 h) 可降低人宫颈癌 HeLa 细胞中 MDM2 蛋白的表达,并在处理 12 h 后提高 p53 蛋白的表达;IU1 (2-100 μM; 12 h) 可提高活化的 caspase-3、活化的 caspase-9 和活化的 caspase-8 的水平,从而促进细胞凋亡。 IU1 (0.1-100 μM; 12 h) 可通过以剂量依赖的方式提升总蛋白泛素化水平,增强 HeLa 人宫颈癌细胞中的 UPS 功能,处理时间为 12 h。 IU1 (0.1-2 μM; 12 h) 可上调 HeLa 人宫颈癌细胞中 p62 和 LC3-II 的蛋白水平,而 IU1 (5-100 μM; 12 h) 可下调该细胞中 p62 的蛋白水平并上调 LC3-II 的蛋白水平;上述作用均在处理 12 h 后出现,提示自噬激活。 IU1 (100 μM; 12 h post 48 h transfection) 可增加转染 pBabe-EGFP-mRFP-LC3 的人宫颈癌细胞 HeLa 中 LC3 斑点的形成,以及自噬体和自溶酶体的数量,证实自噬被激活。 IU1 (4.7-100 μM; ~30 min-2 hr) 可强效且选择性地抑制与蛋白酶体结合的人源 Usp14 的去泛素化活性,其 IC50 为 4.7 μM,且该抑制作用具有完全可逆性。 IU1 (34 μM; 0, 4, 8 min) 可通过抑制 Usp14,在体外增强多泛素化细胞周期蛋白 B 的蛋白酶体降解。 IU1 (25-100 μM; 6 hr) 通过抑制 Usp14 增强蛋白酶体降解作用,从而降低野生型 MEFs 中的 Tau 蛋白水平。 IU1 (10-100 μM; 6 hr) 可通过抑制 Usp14 增强蛋白酶体降解作用,降低野生型 MEF 细胞中扩展型 (Q80) 和野生型 (Q22) 共济失调蛋白-3 的蛋白水平。 IU1 (75 μM; 0, 2, 4, 6, 8 hr) 可降低野生型 MEF 中的 TDP-43 蛋白水平并增强其泛素化修饰,该作用通过抑制 Usp14 来增强蛋白酶体降解实现。 IU1 (50 μM; 6 hr) 不影响野生型 MEF 中不依赖泛素的蛋白酶体底物 cODC-EGFP 的水平,表明其通过抑制 Usp14 发挥的作用对依赖泛素的蛋白酶体底物具有特异性。
Cell Proliferation Assay
| Cell Line: |
ML1 follicular thyroid cancer cells, primary human thyroid cells |
| Concentration: |
1 μM, 3 μM, 5 μM, 10 μM, 20 μM, 30 μM, 50 μM, and 100 μM |
| Incubation Time: |
24 h |
| Result: |
Significantly reduced ML1 cell proliferation at 100 μM. Caused dose-dependent reductions in ML1 cell proliferation at 20, 30, 50, and 100 μM, with 100 μM inducing the strongest effect. Significantly reduced primary thyroid cell proliferation only at 100 μM. |
Western Blot Analysis
| Cell Line: |
ML1 follicular thyroid cancer cells |
| Concentration: |
20-50 μM |
| Incubation Time: |
24 h |
| Result: |
Decreased the total amount of mature 26S proteasome complexes at 20 and 50 μM, with 50 μM inducing a significant reduction. Reduced the amount of USP14-containing 26S proteasome complexes, though this decrease did not reach statistical significance. |
Western Blot Analysis
| Cell Line: |
ML1 follicular thyroid cancer cells, primary human thyroid cells |
| Concentration: |
20 μM (IU1); 100 μM (Chloroquine , co-treatment) |
| Incubation Time: |
24 h (IU1); 4 h (CQ, final incubation) |
| Result: |
Significantly increased LC3B-II levels in ML1 cells when co-treated with 100 μM Chloroquine, indicating enhanced LC3B-dependent autophagy flux. Significantly reduced LC3B-II levels in primary thyroid cells when co-treated with 100 μM Chloroquine, indicating reduced LC3B-dependent autophagy flux.\nDid not cause significant changes in GABARAP-II levels in either ML1 cells or primary thyroid cells when co-treated with 100 μM Chloroquine, indicating no effect on GABARAP-dependent autophagy flux. |
Cell Proliferation Assay
| Cell Line: |
HeLa, SiHa human cervical cancer cells |
| Concentration: |
0.1-100 μM (24 h); 100 μM (12, 24, 48 h) |
| Incubation Time: |
12 h, 24 h, 48 h (100 μM); 24 h (0.1-100 μM) |
| Result: |
Significantly decreased cell proliferation in a dose-dependent and time-dependent manner in both HeLa and SiHa cells. |
Cell Migration Assay
| Cell Line: |
HeLa, SiHa human cervical cancer cells |
| Concentration: |
100 μM |
| Incubation Time: |
24 h, 48 h |
| Result: |
Markedly suppressed wound closure in both HeLa and SiHa cells at 24 and 48 h compared to controls. |
Cell Cycle Analysis
| Cell Line: |
HeLa, SiHa human cervical cancer cells |
| Concentration: |
2, 50, 100 μM (HeLa); 20, 50, 100 μM (SiHa) |
| Incubation Time: |
12 h |
| Result: |
Dramatically induced G0/G1 cell cycle arrest, associated with a decreased population in S/G2/M phases. |
Apoptosis Analysis
| Cell Line: |
HeLa human cervical cancer cells |
| Concentration: |
2, 50, 100 μM |
| Incubation Time: |
12 h |
| Result: |
Significantly increased the relative apoptosis ratio in HeLa cells, with dose-dependent increases in early (Q4), late (Q2), and total apoptotic cells. |
Western Blot Analysis
| Cell Line: |
HeLa human cervical cancer cells |
| Concentration: |
100 μM (MDM2/p53 analysis); 2, 20, 50, 100 μM (caspase analysis) |
| Incubation Time: |
12 h |
| Result: |
Decreased MDM2 protein expression and increased p53 protein expression at 100 μM compared to controls. Increased protein levels of cleaved caspase-3, cleaved caspase-9, and cleaved caspase-8 at 2, 20, 50, and 100 μM. |
Western Blot Analysis
| Cell Line: |
HeLa human cervical cancer cells |
| Concentration: |
0.1-2 μM; 5-100 μM |
| Incubation Time: |
12 h |
| Result: |
Increased p62 and LC3-II protein levels in a dose-dependent manner at 0.1-2 μM. Decreased p62 protein levels and increased LC3-II protein levels in a dose-dependent manner at 5-100 μM. |
Immunofluorescence
| Cell Line: |
HeLa human cervical cancer cells (transfected with pBabe-EGFP-mRFP-LC3) |
| Concentration: |
100 μM |
| Incubation Time: |
12 h (after 48 h vector transfection) |
| Result: |
Significantly increased the number of EGFP and mRFP LC3 puncta per cell, as well as the number of autophagosomes and autolysosomes per cell. |
|